Pharmaxis Ltd
ASX:PXS

Watchlist Manager
Pharmaxis Ltd Logo
Pharmaxis Ltd
ASX:PXS
Watchlist
Price: 0.021 AUD Market Closed
Market Cap: AU$15.1m

Operating Margin

-69.5%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-69.5%
=
Operating Income
AU$-12.7m
/
Revenue
AU$18.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-69.5%
=
Operating Income
AU$-12.7m
/
Revenue
AU$18.3m

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Pharmaxis Ltd
ASX:PXS
15.1m AUD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

In line with most companies in Australia
Percentile
44th
Based on 3 951 companies
44th percentile
-69.5%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Pharmaxis Ltd
Glance View

Market Cap
15.1m AUD
Industry
Pharmaceuticals

Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function test. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm has two approved respiratory products, Bronchitol and Aridol. The Bronchitol is used for the treatment of cystic fibrosis to help patient’s clear mucus from their lungs. Aridol is a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The firm's development pipeline assets include a topical pan-Lysyl Oxidase (LOX) inhibitor in development for scar revision, keloid scarring and scarring from burn wounds; a series of Lysyl Oxidase Like 2 (LOXL2) inhibitors targeting fibrotic diseases of the kidney, lung, liver, and heart; and an anti-inflammatory dual Semicarbazide-Sensitive Amine Oxidase (SSAO)/ Monoamine oxidase B (MAOB) inhibitor targeting Duchenne Muscular Dystrophy.

PXS Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-69.5%
=
Operating Income
AU$-12.7m
/
Revenue
AU$18.3m
What is Pharmaxis Ltd's current Operating Margin?

The current Operating Margin for Pharmaxis Ltd is -69.5%, which is in line with its 3-year median of -69.5%.

How has Operating Margin changed over time?

Over the last 3 years, Pharmaxis Ltd’s Operating Margin has increased from -127% to -69.5%. During this period, it reached a low of -127% on May 30, 2020 and a high of -19.6% on Jun 30, 2021.

Back to Top